|
Paris saponin VII (Chonglou Saponin VII) is a steroidal saponin isolated from the roots and rhizomes of Trillium tschonoskii Maxim. Paris saponin VII-induced apoptosis in K562/ADR cells is associated with Akt/MAPK and the inhibition of P-gp. Paris saponin VII attenuates mitochondrial membrane potential, increases the expression of apoptosis-related proteins, such as Bax and cytochrome c, and decreases the protein expression levels of Bcl-2, caspase-9, caspase-3, PARP-1, and p-Akt. Paris saponin VII induces a robust autophagy in K562/ADR cells and provides a biochemical basis in the treatment of leukemia[1]. Akt p38 Bcl-2 Caspase-9 Caspase-3 PARP-1
Paris saponin VII (Chonglou Saponin VII) inhibits the growth of adriamycin-resistant human leukemia cells (K562/ADR) in a dose-dependent manner. Paris saponin VII significantly suppresses cell proliferation by cell cycle arrest in the G0/G1 phase[1].
Paris saponin VII (Chonglou Saponin VII) (intravenous administration) significantly enhances anticancer efficacy of adriamycin to MCF-7/ADR xenograft model in nude mice[2].
[1]. Yan T, et al. Paris saponin VII induces cell cycle arrest and apoptosis by regulating Akt/MAPK pathway and inhibition of P-glycoprotein in K562/ADR cells. Phytother Res. 2018 May;32(5):898-907. [2]. Li Y, et al. Paris saponin VII reverses chemoresistance in breast MCF-7/ADR cells. J Ethnopharmacol. 2019 Mar 25;232:47-54.
|